Breast cancer in systemic lupus

S. Bernatsky; R. Ramsey-Goldman; M. Petri; M. B. Urowitz; D. D. Gladman; P. F. Fortin; E. Ginzler; J. Romero-Diaz; C. Peschken; S. Jacobsen; J. G. Hanly; C. Gordon; O. Nived; E. H. Yelin; D. Isenberg; A. Rahman; S. C. Bae; L. Joseph; T. Witte; G. Ruiz-Irastorza; C. Aranow; D. Kamen; G. Sturfeldt; W. D. Foulkes; J. E. Hansen; Y. St Pierre; P. Chrétien Raymer; B. Tessier-Cloutier; A. E. Clarke

doi:10.1177/0961203316664595

Breast cancer in systemic lupus

S. Bernatsky^*, R. Ramsey-Goldman, M. Petri, M. B. Urowitz, D. D. Gladman, P. F. Fortin, E. Ginzler, J. Romero-Diaz, C. Peschken, S. Jacobsen, J. G. Hanly, C. Gordon, O. Nived, E. H. Yelin, D. Isenberg, A. Rahman, S. C. Bae, L. Joseph, T. Witte, G. Ruiz-IrastorzaC. Aranow, D. Kamen, G. Sturfeldt, W. D. Foulkes, J. E. Hansen, Y. St Pierre, P. Chrétien Raymer, B. Tessier-Cloutier, A. E. Clarke

^*Corresponding author for this work

Department of Clinical Medicine

16 Citations (Scopus)

Abstract

Objective There is a decreased breast cancer risk in systemic lupus erythematosus (SLE) versus the general population. We assessed a large sample of SLE patients, evaluating demographic and clinical characteristics and breast cancer risk. Methods We performed case-cohort analyses within a multi-center international SLE sample. We calculated the breast cancer hazard ratio (HR) in female SLE patients, relative to demographics, reproductive history, family history of breast cancer, and time-dependent measures of anti-dsDNA positivity, cumulative disease activity, and drugs, adjusted for SLE duration. Results There were 86 SLE breast cancers and 4498 female SLE cancer-free controls. Patients were followed on average for 7.6 years. Versus controls, SLE breast cancer cases tended to be white and older. Breast cancer cases were similar to controls regarding anti-dsDNA positivity, disease activity, and most drug exposures over time. In univariate and multivariate models, the principal factor associated with breast cancers was older age at cohort entry. Conclusions There was little evidence that breast cancer risk in this SLE sample was strongly driven by any of the clinical factors that we studied. Further search for factors that determine the lower risk of breast cancer in SLE may be warranted.

Original language	English
Journal	Lupus
Volume	26
Issue number	3
Pages (from-to)	311-315
Number of pages	5
ISSN	0961-2033
DOIs	https://doi.org/10.1177/0961203316664595
Publication status	Published - Mar 2017

Keywords

Breast cancer
systemic lupus erythematosus

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/0961203316664595

http://europepmc.org/articles/pmc5250552?pdf=renderLicence: Other

Cite this

Bernatsky, S., Ramsey-Goldman, R., Petri, M., Urowitz, M. B., Gladman, D. D., Fortin, P. F., Ginzler, E., Romero-Diaz, J., Peschken, C., Jacobsen, S., Hanly, J. G., Gordon, C., Nived, O., Yelin, E. H., Isenberg, D., Rahman, A., Bae, S. C., Joseph, L., Witte, T., ... Clarke, A. E. (2017). Breast cancer in systemic lupus. Lupus, 26(3), 311-315. https://doi.org/10.1177/0961203316664595

Bernatsky, S, Ramsey-Goldman, R, Petri, M, Urowitz, MB, Gladman, DD, Fortin, PF, Ginzler, E, Romero-Diaz, J, Peschken, C, Jacobsen, S, Hanly, JG, Gordon, C, Nived, O, Yelin, EH, Isenberg, D, Rahman, A, Bae, SC, Joseph, L, Witte, T, Ruiz-Irastorza, G, Aranow, C, Kamen, D, Sturfeldt, G, Foulkes, WD, Hansen, JE, St Pierre, Y, Raymer, PC, Tessier-Cloutier, B & Clarke, AE 2017, 'Breast cancer in systemic lupus', Lupus, vol. 26, no. 3, pp. 311-315. https://doi.org/10.1177/0961203316664595

@article{0f2b531f283d472399ff36ebd35e6504,

title = "Breast cancer in systemic lupus",

abstract = "Objective There is a decreased breast cancer risk in systemic lupus erythematosus (SLE) versus the general population. We assessed a large sample of SLE patients, evaluating demographic and clinical characteristics and breast cancer risk. Methods We performed case-cohort analyses within a multi-center international SLE sample. We calculated the breast cancer hazard ratio (HR) in female SLE patients, relative to demographics, reproductive history, family history of breast cancer, and time-dependent measures of anti-dsDNA positivity, cumulative disease activity, and drugs, adjusted for SLE duration. Results There were 86 SLE breast cancers and 4498 female SLE cancer-free controls. Patients were followed on average for 7.6 years. Versus controls, SLE breast cancer cases tended to be white and older. Breast cancer cases were similar to controls regarding anti-dsDNA positivity, disease activity, and most drug exposures over time. In univariate and multivariate models, the principal factor associated with breast cancers was older age at cohort entry. Conclusions There was little evidence that breast cancer risk in this SLE sample was strongly driven by any of the clinical factors that we studied. Further search for factors that determine the lower risk of breast cancer in SLE may be warranted.",

keywords = "Breast cancer, systemic lupus erythematosus",

author = "S. Bernatsky and R. Ramsey-Goldman and M. Petri and Urowitz, {M. B.} and Gladman, {D. D.} and Fortin, {P. F.} and E. Ginzler and J. Romero-Diaz and C. Peschken and S. Jacobsen and Hanly, {J. G.} and C. Gordon and O. Nived and Yelin, {E. H.} and D. Isenberg and A. Rahman and Bae, {S. C.} and L. Joseph and T. Witte and G. Ruiz-Irastorza and C. Aranow and D. Kamen and G. Sturfeldt and Foulkes, {W. D.} and Hansen, {J. E.} and {St Pierre}, Y. and Raymer, {P. Chr{\'e}tien} and B. Tessier-Cloutier and Clarke, {A. E.}",

year = "2017",

month = mar,

doi = "10.1177/0961203316664595",

language = "English",

volume = "26",

pages = "311--315",

journal = "Lupus",

issn = "0961-2033",

publisher = "SAGE Publications",

number = "3",

}

TY - JOUR

T1 - Breast cancer in systemic lupus

AU - Bernatsky, S.

AU - Ramsey-Goldman, R.

AU - Petri, M.

AU - Urowitz, M. B.

AU - Gladman, D. D.

AU - Fortin, P. F.

AU - Ginzler, E.

AU - Romero-Diaz, J.

AU - Peschken, C.

AU - Jacobsen, S.

AU - Hanly, J. G.

AU - Gordon, C.

AU - Nived, O.

AU - Yelin, E. H.

AU - Isenberg, D.

AU - Rahman, A.

AU - Bae, S. C.

AU - Joseph, L.

AU - Witte, T.

AU - Ruiz-Irastorza, G.

AU - Aranow, C.

AU - Kamen, D.

AU - Sturfeldt, G.

AU - Foulkes, W. D.

AU - Hansen, J. E.

AU - St Pierre, Y.

AU - Raymer, P. Chrétien

AU - Tessier-Cloutier, B.

AU - Clarke, A. E.

PY - 2017/3

Y1 - 2017/3

N2 - Objective There is a decreased breast cancer risk in systemic lupus erythematosus (SLE) versus the general population. We assessed a large sample of SLE patients, evaluating demographic and clinical characteristics and breast cancer risk. Methods We performed case-cohort analyses within a multi-center international SLE sample. We calculated the breast cancer hazard ratio (HR) in female SLE patients, relative to demographics, reproductive history, family history of breast cancer, and time-dependent measures of anti-dsDNA positivity, cumulative disease activity, and drugs, adjusted for SLE duration. Results There were 86 SLE breast cancers and 4498 female SLE cancer-free controls. Patients were followed on average for 7.6 years. Versus controls, SLE breast cancer cases tended to be white and older. Breast cancer cases were similar to controls regarding anti-dsDNA positivity, disease activity, and most drug exposures over time. In univariate and multivariate models, the principal factor associated with breast cancers was older age at cohort entry. Conclusions There was little evidence that breast cancer risk in this SLE sample was strongly driven by any of the clinical factors that we studied. Further search for factors that determine the lower risk of breast cancer in SLE may be warranted.

AB - Objective There is a decreased breast cancer risk in systemic lupus erythematosus (SLE) versus the general population. We assessed a large sample of SLE patients, evaluating demographic and clinical characteristics and breast cancer risk. Methods We performed case-cohort analyses within a multi-center international SLE sample. We calculated the breast cancer hazard ratio (HR) in female SLE patients, relative to demographics, reproductive history, family history of breast cancer, and time-dependent measures of anti-dsDNA positivity, cumulative disease activity, and drugs, adjusted for SLE duration. Results There were 86 SLE breast cancers and 4498 female SLE cancer-free controls. Patients were followed on average for 7.6 years. Versus controls, SLE breast cancer cases tended to be white and older. Breast cancer cases were similar to controls regarding anti-dsDNA positivity, disease activity, and most drug exposures over time. In univariate and multivariate models, the principal factor associated with breast cancers was older age at cohort entry. Conclusions There was little evidence that breast cancer risk in this SLE sample was strongly driven by any of the clinical factors that we studied. Further search for factors that determine the lower risk of breast cancer in SLE may be warranted.

KW - Breast cancer

KW - systemic lupus erythematosus

U2 - 10.1177/0961203316664595

DO - 10.1177/0961203316664595

M3 - Journal article

C2 - 27687028

AN - SCOPUS:85011581256

SN - 0961-2033

VL - 26

SP - 311

EP - 315

JO - Lupus

JF - Lupus

IS - 3

ER -

Breast cancer in systemic lupus

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this